- Home
- URG vs ITOS Comparison
URG vs ITOS Comparison
Compare URG & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URG
- ITOS
- Stock Information
- Founded
- URG 2004
- ITOS 2011
- Country
- URG United States
- ITOS United States
- Employees
- URG N/A
- ITOS N/A
- Industry
- URG Precious Metals
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- URG Basic Materials
- ITOS Health Care
- Exchange
- URG Nasdaq
- ITOS Nasdaq
- Market Cap
- URG 419.5M
- ITOS 381.2M
- IPO Year
- URG N/A
- ITOS 2020
- Fundamental
- Price
- URG $1.41
- ITOS $10.17
- Analyst Decision
- URG Strong Buy
- ITOS Hold
- Analyst Count
- URG 3
- ITOS 6
- Target Price
- URG $2.63
- ITOS $10.60
- AVG Volume (30 Days)
- URG 8.4M
- ITOS 1.5M
- Earning Date
- URG 08-08-2025
- ITOS 08-07-2025
- Dividend Yield
- URG N/A
- ITOS N/A
- EPS Growth
- URG N/A
- ITOS N/A
- EPS
- URG N/A
- ITOS N/A
- Revenue
- URG $33,706,000.00
- ITOS $35,000,000.00
- Revenue This Year
- URG N/A
- ITOS N/A
- Revenue Next Year
- URG $251.38
- ITOS N/A
- P/E Ratio
- URG N/A
- ITOS N/A
- Revenue Growth
- URG 200.09
- ITOS 177.89
- 52 Week Low
- URG $0.55
- ITOS $4.80
- 52 Week High
- URG $1.42
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- URG 75.31
- ITOS 58.43
- Support Level
- URG $1.00
- ITOS $10.10
- Resistance Level
- URG $1.41
- ITOS $10.47
- Average True Range (ATR)
- URG 0.07
- ITOS 0.12
- MACD
- URG 0.01
- ITOS -0.06
- Stochastic Oscillator
- URG 96.05
- ITOS 23.08
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.